Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045708 | 0.84 | ALDH1A1 (0.58) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8223455 | 0.81 | PTGS2 (0.43) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL586588 | 0.81 | MARS1 (0.42) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL6368476 | 0.80 | MARS1 (0.42) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL586319 | 0.79 | DAO (0.43) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL603252 | 0.79 | ALDH1A1 (0.40) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL3086949 | 0.79 | GRIN2D (0.43) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL3939805 | 0.79 | GRIN2D (0.43) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL16960806 | 0.79 | MARS1 (0.39) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B | |
| SCHEMBL14288599 | 0.78 | PTGS2 (0.47) | MARS1ALDH1A1FFAR4GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | claimed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | claimed |
| CN-1878758-A | Crf antagonists and heterobicyclic compounds | ONO PHARMACEUTICAL CO (JP) | 2006-12-13 | — | — | CN | claimed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009019518-A1 | PYRIMIDINE COMPOUNDS HAVING A FGFR INHIBITORY EFFECT | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| CN-1878758-A | Crf antagonists and heterobicyclic compounds | ONO PHARMACEUTICAL CO (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | MARS1 4457/4885ALDH1A1 422/4885FFAR4 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.